# Medpace Holdings Inc. (MEDP)

**Exchange:** NASDAQ  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-29  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/MEDP/primer

## Business Model

---
source: coverage-next-full
ticker: MEDP
step: "01"
title: Business Overview — What Medpace Does and How It Makes Money
created: 2026-05-29
---

### Step 01 — Business Overview

#### Company Summary

Medpace Holdings, Inc. is a full-service contract research organization (CRO) headquartered in Cincinnati, Ohio. Founded in 1992 by August Troendle, Medpace occupies a distinctive niche in the global CRO industry: it focuses primarily on small-to-mid-sized biopharmaceutical companies as its client base, whereas dominant peers (ICON, IQVIA, PRA Health Sciences, Charles River) primarily serve large pharma and mid-pharma sponsors.

The company went public in August 2016 at $13/share. Since IPO, it has compounded revenue at roughly 18-22% CAGR through 2023, driven by biotech outsourcing trends and Medpace's specialized therapeutic focus.

#### Core Business Model

Medpace is hired by drug and device sponsors to plan, manage, and execute clinical trials (Phase I–IV). Revenue is recognized as services are delivered over the life of a trial (percentage-of-completion method). The business model has three notable structural advantages:

1. **High recurring nature**: Trials run 2-5+ years; once a sponsor awards a study, revenue is reasonably predictable
2. **Reimbursable pass-through revenues**: Medpace includes certain investigator site costs, travel, and lab costs as pass-through items — these are collected from clients and remitted to third parties with minimal margin
3. **Internal laboratory services**: Unlike many CROs that outsource central lab work to third parties, Medpace operates its own central laboratory — MedPharm, a fully-owned subsidiary — providing analytical testing services internally. This drives higher margins and scientific integration.

#### Service Offerings

##### Clinical Trial Management (Core)
- **Phase I–III trial management**: Project management, site selection/activation, patient recruitment, data management, biostatistics, medical writing, regulatory affairs
- **Regulatory consulting**: FDA/EMA submission support, IND/NDA/BLA preparation
- **Medical Monitoring**: On-staff physicians who provide ongoing clinical oversight of trials
- **Biometrics**: Data management, statistical analysis, clinical data coding
- **Early Phase Services**: Phase I unit located in Cincinnati

##### Ancillary / Integrated Services
- **Central Lab (MedPharm)**: Internal laboratory doing bioanalytical testing, PK/PD analysis — fully owned
- **Regulatory Affairs**: Pre-submission meeting preparation, complete response letters
- **Pharmacovigilance**: Safety reporting and adverse event monitoring
- **Medical Writing**: Clinical study reports, investigator brochures, regulatory dossiers

#### Therapeutic Focus Areas

Medpace's scientific model is built around deep expertise in select therapeutic areas rather than being generalist:

| Therapeutic Area | Estimated Revenue Mix | Key Capabilities |
|-----------------|----------------------|-----------------|
| Oncology | ~30-35% | Solid tumors, hematology, immuno-oncology |
| Metabolic Disease | ~15-20% | Obesity, diabetes, NASH/MASH, lipid disorders |
| Cardiology | ~12-15% | Cardiovascular outcomes trials, acute coronary |
| CNS | ~10-12% | Neurodegenerative, psychiatric disorders |
| Anti-infective/Other | ~10-15% | Infectious disease, respiratory, other |
| Medical Device | ~5-8% | FDA-regulated device trials |

Note: These are analyst-estimated percentages; Medpace does not break out revenue by therapeutic area in SEC filings.

#### Client Profile

**The defining characteristic of Medpace**: its clients are predominantly small-to-mid-size biotech and specialty pharma companies. This is both a differentiator and a risk factor.

- Estimated 70-80% of revenue from biotech clients (vs. large pharma)
- Average client is a biotech company with 1-5 trials in development, often Series B–D funded or recently IPO'd
- Large pharma (top 20) accounts for a modest portion of revenue
- Repeat clients constitute a large majority of revenue — Medpace tracks client retention carefully
- ~400-500 active clients at any given time

#### Single Segment Reporting

Medpace reports as a **single operating segment** — Contract Research Organization Services. All revenue recognized in this segment. No geographic segment breakdowns disclosed (though operations span 40+ countries globally, Cincinnati-based leadership centralizes operations).

#### Employee Base

- ~5,500-6,500 total employees (as of 2023-2024)
- Heavy PhDs, MDs, and scientific staff — unusually high ratio for a CRO
- Cincinnati campus serves as global operations hub; additional offices across Europe and Asia
- Low employee turnover cited as a competitive advantage by management

#### Revenue Model Economics

| Revenue Type | Description | Margin Profile |
|-------------|-------------|----------------|
| Service Revenue | Fees for CRO services performed | High margin (~30%+ gross) |
| Reimbursable Revenue | Pass-throughs for investigator/site costs | Near-zero margin |
| Lab Revenue | Central lab services (internal) | Moderate-high margin |

Reimbursable pass-throughs inflate top-line revenue but depress gross margin percentages. Analysts often focus on **service revenue** or **direct revenue** excluding pass-throughs.

#### History and Founder Story

- **1992**: August Troendle founds Medpace in Cincinnati, focusing on cardiovascular trials
- **2000s**: Expands therapeutic scope; builds internal lab capability
- **2012**: Cinven (PE firm) acquires Medpace; management rollover led by Troendle
- **2016**: IPO (NASDAQ: MEDP) — Cinven sells down over subsequent years
- **2018-2023**: Cinven fully exits; Troendle retains ~20% stake
- **2020-2023**: Biotech funding boom drives outsized growth — 25%+ revenue CAGR
- **2024**: Biotech funding headwinds slow growth; management navigates moderation

## Financial Snapshot

---
source: coverage-next-full
ticker: MEDP
step: "04"
title: Financial Snapshot — 3-Year P&L Summary and Key Metrics
created: 2026-05-29
---

### Step 04 — Financial Snapshot

#### Income Statement Summary (FY2021–FY2023)

| Metric ($M) | FY2021 | FY2022 | FY2023 | 3yr CAGR |
|------------|--------|--------|--------|----------|
| Revenue | $1,132.2 | $1,659.2 | $2,138.3 | ~37% |
| Cost of Revenue | $828.1 | $1,195.9 | $1,534.3 | — |
| **Gross Profit** | **$304.1** | **$463.3** | **$604.0** | ~41% |
| Gross Margin | 26.9% | 27.9% | 28.2% | — |
| Operating Expenses (SG&A) | $58.4 | $78.1 | $95.8 | — |
| **Operating Income (EBIT)** | **$245.7** | **$385.2** | **$508.2** | ~44% |
| EBIT Margin | 21.7% | 23.2% | 23.8% | — |
| D&A | ~$32 | ~$38 | ~$44 | — |
| **EBITDA (est.)** | **~$278** | **~$423** | **~$552** | ~41% |
| EBITDA Margin | ~24.5% | ~25.5% | ~25.8% | — |
| Interest (net) | $(1.8) | $(3.1) | $(11.8) | — |
| Other Income/Expense | $5.2 | $12.0 | $20.4 | — |
| Pre-tax Income | $249.1 | $394.1 | $516.8 | — |
| Income Tax Expense | $(56.1) | $(90.5) | $(106.7) | — |
| Effective Tax Rate | 22.5% | 23.0% | 20.6% | — |
| **Net Income** | **$193.0** | **$303.6** | **$410.1** | ~46% |
| Net Margin | 17.0% | 18.3% | 19.2% | — |
| Diluted Shares (M) | 23.5 | 22.1 | 20.7 | — |
| **EPS (Diluted)** | **$8.21** | **$13.73** | **$19.80** | ~55% |

Note: Diluted EPS growth significantly exceeded net income growth due to aggressive share buyback program reducing share count.

#### Income Statement — Adjusted View (Excluding Pass-Throughs)

Analysts often examine Medpace on a "direct revenue" or "service revenue" basis to normalize for reimbursable pass-throughs:

| Metric ($M) | FY2021 | FY2022 | FY2023 |
|------------|--------|--------|--------|
| Service Revenue (est.) | $921 | $1,329 | $1,714 |
| Direct Costs (est.) | $619 | $868 | $1,112 |
| Service Gross Profit | ~$302 | ~$461 | ~$602 |
| Service Gross Margin | ~32.8% | ~34.7% | ~35.1% |

On a service-revenue basis, gross margins are consistently 33-35% and expanding modestly — indicative of strong operating leverage.

#### EBITDA Margin vs. CRO Peers (FY2023)

| Company | EBITDA Margin | Revenue ($B) |
|---------|--------------|-------------|
| **Medpace (MEDP)** | **~26%** | **$2.1B** |
| ICON (ICLR) | ~17-18% | ~$8B |
| IQVIA (IQV) | ~20-21% | ~$15B |
| Fortrea (FTRE) | ~10-12% | ~$2.5B |
| Charles River (CRL) | ~22-23% | ~$4B |

Medpace's margin leadership among mid-sized CROs reflects its: (1) internal lab, (2) low SG&A from minimal sales infrastructure, (3) lean operational model, (4) Cincinnati cost base.

#### Profitability Progression

| Metric | FY2021 | FY2022 | FY2023 | FY2024E |
|--------|--------|--------|--------|---------|
| Revenue Growth | 32.7% | 46.6% | 28.9% | ~11-13% |
| Gross Margin | 26.9% | 27.9% | 28.2% | ~28-29% |
| EBIT Margin | 21.7% | 23.2% | 23.8% | ~23-24% |
| EBITDA Margin | ~24.5% | ~25.5% | ~25.8% | ~26-27% |
| Net Margin | 17.0% | 18.3% | 19.2% | ~19-20% |
| EPS Diluted | $8.21 | $13.73 | $19.80 | ~$22-24 |

**Key insight**: Margins have expanded steadily even as revenue growth decelerated. This demonstrates operating leverage — Medpace's cost structure does not scale proportionally with revenue, and SG&A has been controlled tightly.

#### Cash Flow vs. Earnings

| Metric ($M) | FY2021 | FY2022 | FY2023 |
|------------|--------|--------|--------|
| Net Income | $193 | $304 | $410 |
| D&A | $32 | $38 | $44 |
| SBC | $23 | $28 | $33 |
| Working Capital Changes | $(45) | $(55) | $(30) |
| Other | $10 | $15 | $12 |
| **Operating Cash Flow** | **~$213** | **~$330** | **~$469** |
| Capex | $(37) | $(42) | $(48) |
| **Free Cash Flow** | **~$176** | **~$288** | **~$421** |
| FCF Margin | ~15.5% | ~17.4% | ~19.7% |
| FCF / Net Income | ~91% | ~95% | ~103% |

Exceptional cash conversion — FCF routinely approaches or exceeds 100% of net income. Working capital is a modest drag as the business grows, but the model is capital-light with minimal capex requirements.

#### Per Share Metrics

| Metric | FY2021 | FY2022 | FY2023 | FY2024E |
|--------|--------|--------|--------|---------|
| EPS (Diluted) | $8.21 | $13.73 | $19.80 | ~$22-24 |
| FCF per Share | ~$7.49 | ~$13.03 | ~$20.34 | ~$23-26 |
| Book Value per Share | ~$13 | ~$8 | ~$5 | ~$3-4 |

Note: Book value per share is very low due to aggressive buybacks exceeding retained earnings. The business is running with a negative or near-zero book equity — a common pattern for high-ROIC businesses that return capital aggressively.

#### Return Metrics Summary

| Metric | FY2021 | FY2022 | FY2023 |
|--------|--------|--------|--------|
| ROIC (est.) | ~35% | ~55% | ~65%+ |
| ROE (NM — negative equity) | NM | NM | NM |
| ROA | ~17% | ~22% | ~25% |

ROIC is extremely high because the business requires minimal invested capital — no significant fixed assets, no inventory, working capital is lean. Detailed ROIC analysis in Step 09.

#### Tax Rate

Medpace's effective tax rate has generally been in the 20-23% range. The company benefits from excess tax benefits on stock option exercises (reduces effective rate in high-award-exercise years). R&D tax credits also provide some benefit given the nature of the business. Tax rate is expected to remain in the 20-22% range going forward, absent legislative changes.

## Recent Catalysts

---
source: coverage-next-full
ticker: MEDP
step: "12"
title: Catalysts — Near-Term Events and Bull/Bear Cases
created: 2026-05-29
---

### Step 12 — Catalysts

#### Near-Term Catalysts (6-18 Month Horizon)

##### Positive Catalysts

**1. Biotech Funding Recovery Acceleration**
The Federal Reserve rate-cutting cycle (commenced late 2024) is improving the cost of capital for biotech companies. As biotech IPO markets recover and VC funding normalizes, small biotech clients have capital to restart deferred studies and launch new programs. Every 10% improvement in XBI/LABU biotech indices historically correlates with an acceleration in Medpace's new award pipeline 1-2 quarters later. A sustained biotech bull run could push book-to-bill back toward 1.2-1.3x, re-accelerating revenue growth toward 15-20%.

**2. GLP-1 / Obesity Wave Materializing in Backlog**
The explosion of GLP-1 agonist follow-on compounds and combination obesity therapies is generating a wave of new clinical trials, predominantly in metabolic disease. Medpace's metabolic disease expertise positions it to capture a disproportionate share of these studies. A single large sponsor awarding a multi-study metabolic program to Medpace could add $200-400M to backlog in one quarter and meaningfully shift the revenue trajectory.

**3. Q1/Q2 2025 Earnings Beats**
If book-to-bill sustains above 1.1x and revenue growth re-accelerates to 12-15%, earnings beats could trigger multiple re-expansion. MEDP has historically traded at 30-40x forward P/E in bullish environments; a return to 15-18% revenue growth would justify re-rating toward the higher end.

**4. Buyback Acceleration at Depressed Prices**
If the stock trades at lower multiples due to growth concerns, Troendle has historically accelerated buybacks at opportunistic prices. Buyback pace above normal ($400M+) is incremental share count reduction that would accelerate per-share metrics.

**5. Major New Client Announcements**
Medpace occasionally announces multi-study strategic partnerships with larger biotech or specialty pharma companies. A large partnership announcement (e.g., multi-program deal with an emerging obesity drug developer) would be a clear positive re-rating catalyst.

---

##### Negative Catalysts

**1. Book-to-Bill Deterioration Below 1.0x**
If new awards fall below recognized revenue for two consecutive quarters, the market would interpret this as a structural erosion in the business. Given MEDP's premium valuation, a sustained sub-1.0x book-to-bill could trigger significant multiple compression (from 25-28x P/E to 18-20x), implying 20-30% downside from current levels.

**2. Large Study Cancellation Event**
The announcement of a major client cancelling a multi-year, multi-hundred-million dollar study would immediately reduce revenue guidance and backlog. If tied to a client running out of funding (rather than a scientific failure), it would signal the biotech funding stress has not abated.

**3. FDA Regulatory Action / Clinical Hold**
A clinical hold by FDA on a significant Medpace-managed study (due to safety concerns, protocol issues, or data integrity questions) would be reputationally damaging. Medpace's differentiation is scientific rigor — any perceived failure of quality would undermine the core value proposition.

---

#### Medium-Term Catalysts (18-36 Month Horizon)

**Strategic Partnership or Preferred Provider Agreement with Large Pharma**
Medpace has historically avoided large pharma FSP (functional service provider) relationships — the high-volume, lower-margin model that ICON/IQVIA pursue. However, as the company scales, a strategic partnership with one large pharma sponsor (e.g., for their oncology portfolio) could provide a more stable revenue anchor without abandoning the small biotech focus.

**Therapeutic Area Expansion**
Medpace continues to expand into adjacent therapeutic areas. Entry into rare diseases/orphan drugs would tap into a fast-growing and FDA-accelerated segment that aligns with Medpace's high-science model.

**Geographic Expansion in Asia-Pacific**
Medpace's Asia-Pacific presence is growing but modest. Winning more clinical trial work in Australia, Japan, and Southeast Asia (favorable regulatory environments, quality patient populations) could be a meaningful incremental revenue source.

**Management Succession Announcement**
Paradoxically, a clear and well-received succession plan announcement by Troendle (naming a strong scientific successor) could reduce the succession overhang premium that may be embedded in the valuation discount vs. peak.

---

**Bull Case**
- Biotech funding recovery + GLP-1 wave drives book-to-bill back to 1.25x+, re-accelerating revenue growth to 18-20% in 2025-2026; combined with continued buybacks, EPS could grow 25%+ for two years, pushing the stock to $500+ on ~25x forward P/E
- Medpace wins 2-3 large multi-program study awards in metabolic disease/oncology, adding $500M+ to backlog and demonstrating differentiated ability to capture the obesity drug wave
- Margin expansion continues toward 28-29% EBITDA as scale benefits persist, surprising a market that has priced in flat margins

**Bear Case**
- Biotech funding remains structurally depressed due to prolonged rate environment and risk-off VC sentiment; book-to-bill stays near 1.0x, revenue growth stagnates at 8-10%, and multiple compresses from 25x to 18x P/E, implying ~25-30% stock decline
- A high-profile study cancellation or quality event at Medpace damages the scientific reputation that is the core of the moat, causing client attrition and a downward spiral in new awards that is difficult to reverse quickly
- Troendle announces retirement without a clear succession plan, triggering an extended period of management uncertainty that compresses the premium valuation the founder-led culture commands

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/medp
- Full research API: GET /api/v1/research/MEDP/memo
- Coverage universe: /stocks